Impaired hepatic removal of interleukin-6 in patients with liver cirrhosis

Cytokine

Volumn 53, Issue 2, 2011, Pages 178-183

  Wiest, Reiner ^a   Weigert, Johanna ^a   Wanninger, Josef ^a   Neumeier, Markus ^a   Bauer, Sabrina ^a   Schmidhofer, Sandra ^a   Farkas, Stefan ^a   Scherer, Marcus N ^a   Schäffler, Andreas ^a   Schölmerich, Jürgen ^a   Buechler, Christa ^a  

^a UNIVERSITY HOSPITAL REGENSBURG   (Germany)

Author keywords

Hepatic vein; Interleukin 6; Liver cirrhosis; Portal vein

Indexed keywords

INTERLEUKIN 6;

ADULT; AGED; ALCOHOL LIVER CIRRHOSIS; ARTICLE; ASCITES; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DISEASE CLASSIFICATION; FEMALE; HUMAN; LIVER CIRRHOSIS; LIVER CLEARANCE; LIVER DYSFUNCTION; LIVER FUNCTION; LIVER VEIN; MALE; PORTAL VEIN BLOOD; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN TRANSPORT; SYSTEMIC CIRCULATION; TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT;

ADULT; AGED; ANTHROPOMETRY; ASCITES; CASE-CONTROL STUDIES; DEMOGRAPHY; FEMALE; HUMANS; INTERLEUKIN-6; LIVER; LIVER CIRRHOSIS; LIVER FUNCTION TESTS; MALE; MIDDLE AGED; PORTAL VEIN;

EID: 78651093454     PISSN: 10434666     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cyto.2010.06.013     Document Type: Article

References (33)

1. Andus T., Bauer J., Gerok W. Effects of cytokines on the liver. Hepatology 1991, 13:364-375.
2. Mohamed-Ali V., Goodrick S., Rawesh A., Katz D.R., Miles J.M., Yudkin J.S., et al. Subcutaneous adipose tissue releases interleukin-6, but not tumor necrosis factor-alpha, in vivo. J Clin Endocrinol Metab 1997, 82:4196-4200.
3. Tacke F., Luedde T., Trautwein C. Inflammatory pathways in liver homeostasis and liver injury. Clin Rev Allergy Immunol 2009, 36:4-12.
4. Castell J.V., Gomez-Lechon M.J., David M., Andus T., Geiger T., Trullenque R., et al. Interleukin-6 is the major regulator of acute phase protein synthesis in adult human hepatocytes. FEBS Lett 1989, 242:237-239.
5. Fontana L., Eagon J.C., Trujillo M.E., Scherer P.E., Klein S. Visceral fat adipokine secretion is associated with systemic inflammation in obese humans. Diabetes 2007, 56:1010-1013.
6. Deviere J., Content J., Denys C., Vandenbussche P., Schandene L., Wybran J., et al. High interleukin-6 serum levels and increased production by leucocytes in alcoholic liver cirrhosis. Correlation with IgA serum levels and lymphokines production. Clin Exp Immunol 1989, 77:221-225.
7. Mackenzie I., Woodhouse J. C-reactive protein concentrations during bacteraemia: a comparison between patients with and without liver dysfunction. Intensive Care Med 2006, 32:1344-1351.
8. Soresi M., Giannitrapani L., D'Antona F., Florena A.M., La Spada E., Terranova A., et al. Interleukin-6 and its soluble receptor in patients with liver cirrhosis and hepatocellular carcinoma. World J Gastroenterol 2006, 12:2563-2568.
9. Lemmers A., Gustot T., Durnez A., Evrard S., Moreno C., Quertinmont E., et al. An inhibitor of interleukin-6 trans-signalling, sgp130, contributes to impaired acute phase response in human chronic liver disease. Clin Exp Immunol 2009, 156:518-527.
10. Cichoz-Lach H., Celinski K., Slomka M., Kasztelan-Szczerbinska B. Pathophysiology of portal hypertension. J Physiol Pharmacol 2008, 59(Suppl. 2):231-238.
11. Klein C., Wustefeld T., Assmus U., Roskams T., Rose-John S., Muller M., et al. The IL-6-gp130-STAT3 pathway in hepatocytes triggers liver protection in T cell-mediated liver injury. J Clin Invest 2005, 115:860-869.
12. Wuestefeld T., Klein C., Streetz K.L., Beraza N., Scholmerich J., Burgart L.J., et al. Lack of gp130 expression results in more bacterial infection and higher mortality during chronic cholestasis in mice. Hepatology 2005, 42:1082-1090.
13. Ezure T., Sakamoto T., Tsuji H., Lunz J.G., Murase N., Fung J.J., et al. The development and compensation of biliary cirrhosis in interleukin-6-deficient mice. Am J Pathol 2000, 156:1627-1639.
14. Sakamoto T., Liu Z., Murase N., Ezure T., Yokomuro S., Poli V., et al. Mitosis and apoptosis in the liver of interleukin-6-deficient mice after partial hepatectomy. Hepatology 1999, 29:403-411.
15. Febbraio M.A., Ott P., Nielsen H.B., Steensberg A., Keller C., Krustrup P., et al. Hepatosplanchnic clearance of interleukin-6 in humans during exercise. Am J Physiol Endocrinol Metab 2003, 285:E397-E402.
16. Garibotto G., Sofia A., Balbi M., Procopio V., Villaggio B., Tarroni A., et al. Kidney and splanchnic handling of interleukin-6 in humans. Cytokine 2007, 37:51-54.
17. Deaciuc I.V., Alappat J.M., McDonough K.H., D'Souza N.B. Interleukin-6 tumor necrosis factor-alpha clearance and metabolism in vivo and by the isolated, perfused liver in the rat: effect of acute alcohol administration. Alcohol Clin Exp Res 1996, 20:293-301.
18. Jiao J., Friedman S.L., Aloman C. Hepatic fibrosis. Curr Opin Gastroenterol 2009, 25:223-229.
19. Andus T., Gross V., Holstege A., Weber M., Ott M., Gerok W., et al. Evidence for the production of high amounts of interleukin-6 in the peritoneal cavity of patients with ascites. J Hepatol 1992, 15:378-381.
20. Bac D.J., Pruimboom W.M., Mulder P.G., Zijlstra F.J., Wilson J.H. High interleukin-6 production within the peritoneal cavity in decompensated cirrhosis and malignancy-related ascites. Liver 1995, 15:265-270.
21. Genesca J., Gonzalez A., Segura R., Catalan R., Marti R., Varela E., et al. Interleukin-6, nitric oxide, and the clinical and hemodynamic alterations of patients with liver cirrhosis. Am J Gastroenterol 1999, 94:169-177.
22. Moller S., Henriksen J.H., Bendtsen F. Pathogenetic background for treatment of ascites and hepatorenal syndrome. Hepatol Int 2008, 2:416-428.
23. Wu C.W., Wang S.R., Chao M.F., Wu T.C., Lui W.Y., P'Eng F.K., et al. Serum interleukin-6 levels reflect disease status of gastric cancer. Am J Gastroenterol 1996, 91:1417-1422.
24. Rossle M., Haag K., Ochs A., Sellinger M., Noldge G., Perarnau J.M., et al. The transjugular intrahepatic portosystemic stent-shunt procedure for variceal bleeding. N Engl J Med 1994, 330:165-171.
25. Weigert J., Neumeier M., Wanninger J., Filarsky M., Bauer S., Wiest R., et al. Systemic chemerin is related to inflammation rather than obesity in type 2 diabetes. Clin Endocrinol (Oxf) 2010, 72:342-348.
26. Weigert J., Neumeier M., Wanninger J., Bauer S., Farkas S., Scherer M.N., et al. Serum galectin-3 is elevated in obesity and negatively correlates with glycosylated hemoglobin in type 2 diabetes. J Clin Endocrinol Metab 2010, 95:1404-1411.
27. Streetz K.L., Tacke F., Leifeld L., Wustefeld T., Graw A., Klein C., et al. Interleukin 6/gp130-dependent pathways are protective during chronic liver diseases. Hepatology 2003, 38:218-229.
28. Schuett H., Luchtefeld M., Grothusen C., Grote K., Schieffer B. How much is too much? Interleukin-6 and its signalling in atherosclerosis. Thromb Haemost 2009, 102:215-222.
29. Wright G., Davies N.A., Shawcross D.L., Hodges S.J., Zwingmann C., Brooks H.F., et al. Endotoxemia produces coma and brain swelling in bile duct ligated rats. Hepatology 2007, 45:1517-1526.
30. Matloff D.S., Selinger M.J., Kaplan M.M. Hepatic transaminase activity in alcoholic liver disease. Gastroenterology 1980, 78:1389-1392.
31. Zhang W., Yue B., Wang G.Q., Lu S.L. Serum and ascites levels of macrophage migration inhibitory factor, TNF-alpha and IL-6 in patients with chronic virus hepatitis B and hepatitis cirrhosis. Hepatobiliary Pancreat Dis Int 2002, 1:577-580.
32. Cariello R., Federico A., Sapone A., Tuccillo C., Scialdone V.R., Tiso A., et al. Intestinal permeability in patients with chronic liver diseases: its relationship with the aetiology and the entity of liver damage. Dig Liver Dis 2010, 42:200-204.
33. Starkel P., Bishop K., Horsmans Y., Strain A.J. Expression and DNA-binding activity of signal transducer and activator of transcription 3 in alcoholic cirrhosis compared to normal liver and primary biliary cirrhosis in humans. Am J Pathol 2003, 162:587-596.